Experimental combo for tough blood cancers hits early hurdle
NCT ID NCT04937166
First seen Nov 11, 2025 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This early-stage trial tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine and venetoclax) in 25 people with relapsed or hard-to-treat acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. The study aimed to check safety and find the right dose, but it was terminated early. It is too soon to know if this approach will help patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
The University of Texas MD Anderson Cancer Center, Department of Leukemia
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DSP107 (a fusion protein) combined with azacitidine and venetoclax
What this could lead to
If successful, this could point toward a new combination treatment for certain blood cancers that have not responded to prior therapy.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The combination may cause significant side effects, and it is unclear if it will work better than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.